Technology & Pipeline
Translating Mechanistic Insights into Precision Therapeutics
CELLTIUM is a preclinical-stage biotechnology company developing precision therapies for CMT1A and related peripheral neuropathies. Our approach combines deep neurobiological expertise with the proprietary PRECISION™ platform to drive translationally informed drug discovery.
CMT1A Pipeline: Targeting the Root Cause
CMT1A is a genetically defined peripheral neuropathy characterized by progressive nerve dysfunction and complex downstream pathology, including demyelination and axonal degeneration. Despite its clear genetic basis, there is still no approved disease-modifying treatment.
At CELLTIUM, we focus on the underlying mechanisms that drive disease progression rather than symptom management alone. Our small-molecule portfolio includes multiple candidates from distinct chemical series that have demonstrated compelling preclinical efficacy in established CMT1A disease models, including evidence of improvement in peripheral nerve biology and function.
PRECISION™: AI-Driven Neuro-Phenomics
PRECISION™ is our proprietary platform for neuro-phenomic drug discovery, integrating proprietary peripheral nerve models developed by CELLTIUM, high-content phenotypic screening, and multimodal biological data. It generates actionable phenomic signatures that guide compound prioritization and lead optimization.
Moving Toward the Clinic
By linking biological insight with platform-based decision-making, CELLTIUM is working to narrow the gap between preclinical models and human disease biology. We are advancing our lead small-molecule assets through IND-enabling studies with the goal of delivering meaningful therapeutic benefit to patients with CMT1A and related rare neurological disorders.